{"id":"antiretroviral-therapy-plus-interleukin-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune activation syndrome"},{"rate":null,"effect":"Capillary leak syndrome (IL-2 related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Antiretroviral therapy (ART) directly inhibits HIV replication through various mechanisms (reverse transcriptase inhibition, protease inhibition, integrase inhibition, or entry inhibition). Interleukin-2 (IL-2) is a cytokine that stimulates proliferation and activation of T cells and natural killer cells, augmenting the immune response to control viral replication and restore immune competence in HIV-infected patients.","oneSentence":"This combination uses antiretroviral drugs to suppress HIV replication while interleukin-2 enhances immune cell proliferation and function to restore CD4+ T-cell counts.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:27:36.953Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV infection with CD4+ T-cell restoration"}]},"trialDetails":[{"nctId":"NCT03308786","phase":"PHASE2","title":"HIV Reservoir Reduction With Interleukin-2","status":"TERMINATED","sponsor":"Case Western Reserve University","startDate":"2019-04-01","conditions":"HIV Infection","enrollment":9},{"nctId":"NCT01013415","phase":"PHASE1","title":"CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2001-09","conditions":"HIV-1 Infections","enrollment":17},{"nctId":"NCT04724629","phase":"PHASE3","title":"Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2021-01-05","conditions":"Covid19","enrollment":60},{"nctId":"NCT00004978","phase":"PHASE3","title":"An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-03","conditions":"HIV Infections","enrollment":4150},{"nctId":"NCT00110812","phase":"PHASE2","title":"Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"HIV Infections","enrollment":267},{"nctId":"NCT00006066","phase":"PHASE1","title":"Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":92},{"nctId":"NCT00015704","phase":"NA","title":"Effect of Interleukin-2 on HIV Treatment Interruption","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":80},{"nctId":"NCT00000948","phase":"PHASE2","title":"Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1998-02","conditions":"HIV Infections","enrollment":72},{"nctId":"NCT00000825","phase":"PHASE2","title":"The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1998-05","conditions":"HIV Infections","enrollment":72},{"nctId":"NCT00000909","phase":"PHASE2","title":"A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":36},{"nctId":"NCT00000889","phase":"PHASE2","title":"A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1997-10","conditions":"HIV Infections","enrollment":72},{"nctId":"NCT00000820","phase":"PHASE2","title":"A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":104},{"nctId":"NCT00001131","phase":"NA","title":"Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-05","conditions":"HIV Infections","enrollment":42},{"nctId":"NCT01081808","phase":"PHASE1","title":"Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors","status":"TERMINATED","sponsor":"Roger Williams Medical Center","startDate":"2009-10","conditions":"Neoplasms, Tumors, Solid Tumors","enrollment":2},{"nctId":"NCT00059462","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-12","conditions":"HIV Infections","enrollment":56},{"nctId":"NCT02300623","phase":"PHASE4","title":"Intermittent ART in Primary HIV Infection","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2000-03","conditions":"HIV","enrollment":12},{"nctId":"NCT00979706","phase":"PHASE4","title":"Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD).","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2005-03","conditions":"HIV","enrollment":22},{"nctId":"NCT00006154","phase":"PHASE3","title":"A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":165},{"nctId":"NCT00003575","phase":"PHASE2","title":"Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-01","conditions":"Lymphoma","enrollment":40},{"nctId":"NCT00000870","phase":"PHASE2","title":"A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00000923","phase":"NA","title":"Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":110},{"nctId":"NCT00113282","phase":"PHASE2","title":"Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2004-06","conditions":"HIV Infections","enrollment":57},{"nctId":"NCT00013611","phase":"PHASE3","title":"Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2001-03","conditions":"HIV Infection","enrollment":1695},{"nctId":"NCT00071890","phase":"PHASE2","title":"Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-10","conditions":"HIV Infections","enrollment":148},{"nctId":"NCT00196651","phase":"PHASE2","title":"HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection","status":"TERMINATED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2000-08","conditions":"HIV Infection","enrollment":60},{"nctId":"NCT00002449","phase":"PHASE1","title":"Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy","status":"UNKNOWN","sponsor":"Chiron Corporation","startDate":"1999-08","conditions":"HIV Infections","enrollment":212},{"nctId":"NCT00002321","phase":"PHASE1","title":"A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis","status":"COMPLETED","sponsor":"Chiron Corporation","startDate":"","conditions":"Cytomegalovirus Retinitis, HIV Infections","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":50,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IL-2","Stavudine","Lamivudine","Indinavir"],"phase":"marketed","status":"active","brandName":"Antiretroviral therapy plus Interleukin-2","genericName":"Antiretroviral therapy plus Interleukin-2","companyName":"Juan A. Arnaiz","companyId":"juan-a-arnaiz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses antiretroviral drugs to suppress HIV replication while interleukin-2 enhances immune cell proliferation and function to restore CD4+ T-cell counts. Used for HIV infection with CD4+ T-cell restoration.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}